Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn’s Fistulas: A Case Report
Authors:
- Marieke C BarnhoornMBMarieke C Barnhoorn
- Astrid G S Van HalterenAHAstrid G S Van Halteren
- Melissa Van PelMPMelissa Van Pel
- Ilse MolendijkIMIlse Molendijk
- Patty M JansenPJPatty M Jansen
- Gerard DijkstraGDGerard Dijkstra
- Liesbeth E M OostenLOLiesbeth E M Oosten
- Andrea E Van der Meulen – de JongAJAndrea E Van der Meulen – de Jong
Open Access
- 18 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (6) , 807-811
Abstract
Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.Keywords
This publication has 18 references indexed in Scilit:
- Allogeneic Bone Marrow–Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn’s DiseaseGastroenterology, 2015
- Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2015
- Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort studyAnnals of Oncology, 2014
- Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host diseaseBritish Journal of Haematology, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2011
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort studyThe Lancet, 2009
- Immunodeficiency-associated lymphomasBlood Reviews, 2008
- Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literatureMedical Oncology, 2008
- Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host DiseaseTransplantation, 2006